Sanofi S.A., FR0000120578

RBC cuts Sanofi target to EUR 75.00: Sanofi stock trades 0.12 percent above it

Published on 10/27/2026 at 17:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi reports third-quarter results on October 30, 2026. Sanofi stock costs EUR 75.09 on October 27, 2026, 0.23 percent above the Xetra close.

Analyst target and results date

RBC cut its Sanofi target from EUR 80.00 to EUR 75.00 on October 16, 2026.
Sanofi will publish third-quarter 2026 results on October 30, 2026.
Sanofi stock costs EUR 75.09 at Lang & Schwarz on October 27, 2026, 0.23 percent above the Xetra close of October 26, 2026 at EUR 74.92.

Sanofi S.A., FR0000120578, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) faced a lower analyst valuation after MarketScreener reported on October 16, 2026 that RBC cut its target from EUR 80.00 to EUR 75.00 and retained a Sector Perform rating. The new target sits 0.12 percent below the euro quote of EUR 75.09. Sanofi stock was trading at EUR 75.09 at Lang & Schwarz on October 27, 2026 at 5:07 p.m. CEST, 0.23 percent above the Xetra close of October 26, 2026 at EUR 74.92.

The target now meets the quote

The narrow gap between the RBC target and Sanofi's euro quotation makes the analyst revision the clearest valuation marker. The calculation uses the EUR 75.00 target and the EUR 75.09 Lang & Schwarz price, placing the stock 0.12 percent above the target. RBC's Sector Perform rating adds a neutral assessment to the target reduction.

Nasdaq range shows a wider frame

Sanofi's Nasdaq-listed American depositary receipt was at USD 41.72 on October 27, 2026 at 12:13 p.m. EDT. The quoted 52-week range was USD 39.07 to USD 52.68, while market capitalization stood at USD 100.0 billion and volume at 705,978 shares. The home listing remains on Euronext Paris under the ticker SAN.

Results arrive on October 30

Sanofi's investor calendar schedules the third-quarter 2026 results for October 30, 2026, with a management presentation and question-and-answer session from 1:30 p.m. to 2:30 p.m. CET, according to Sanofi. The date is the next concrete company event for the stock. Sanofi's standardized trailing price-to-earnings ratio was 23.22 on October 27, 2026, adding a valuation measure to the upcoming results date.

Business scale remains substantial

MarketScreener describes Sanofi as a European pharmaceutical group whose portfolio includes prescription medicines and vaccines. Its company profile states that Sanofi had 37 production sites at the end of 2025. That historical operating footprint provides context for the scale behind the forthcoming quarterly figures.

Euro quote remains near target

The EUR 75.09 Lang & Schwarz quote stood 0.23 percent above the Xetra close of October 26, 2026 at EUR 74.92. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.